

10/539879

JC06 Rec'd PCT/PTO, 16 JUN 2005

"Express Mail" mailing label number EV530260436US

#2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Patent Application of Florence Henry, <i>et al.</i>	:	Group Art Unit:
		:	
		:	
Appln. No.:		:	Examiner: Unknown
		:	
Filed:		:	Confirmation No.:
		:	
For:	USE OF AN EXTRACT FROM THE PLANT ARGANIA SPINOSA	:	Attorney Docket No.: C 2766 PCT/US

Customer No.: 23657

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is an Information Disclosure Statement ("IDS") in the above-referenced application, together with an IDC form listing all references cited and a copy of each reference (unless the reference is a U.S. patent application).

This IDS is being mailed within three months of filing of the above-captioned application, if it is a national application, or within three months of entering, as set forth in 37 C.F.R. § 1.491, the national stage of the above-captioned application, if the above-captioned application is an international application. Therefore, consideration of the IDS by the Patent and Trademark Office, without the payment of any additional fee, is believed to be due under 37 C.F.R. § 1.97(b).

Some of the references are neither in English nor cited in any previously submitted accompanying English language version of a search report by another patent office, and therefore require a concise explanation of relevancy, as it is currently

Docket No. : C 2766 PCT/US

understood by the applicant, pursuant to 37 C.F.R. § 1.98(a)(3). This required explanation of relevancy is given in the specification of the above-captioned application for the following references:

Reference Identification

Alaoui et al., "Activite analgesique et anti-inflammatoire des saponines d'Argania spinosa", Annales pharmaceutique francaises, 1998, pgs 220-228

Hagers Handbuch der pharmazeutischen Praxis, vol. 2, 1991, pgs 1026-1030


Berrada et al., "Mise en évidence expérimentale des effets antihypertenseurs et hypocholestérolémiant de l'huile d'Argan, Argania sideroxylon", Thérapie 2000, pgs 375-378
(listed on a European Search Report which is unavailable).

Described in Specification at:

Page 2, lines 9-11

Page 6, line 26 - Page 7, line 4

Respectfully submitted,



Daniel S. Ortiz
(Reg. No. 25,123)
Attorney for Applicant(s)
215-628-1141

Cognis Corporation
Law Department
300 Brookside Avenue
Ambler, PA 19002

DSO/mc G:\IDC\C2766ids.doc

Enclosure

1. International Search Report (English Language)
2. IDC w/references

JC06 Rec'd PCT/PTO 16 JUN 2005

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1
-------	---

1

1

2

cket

N

Complete if Known

own 10/539879

Application Number

Filing Date

First Named Inventor

Florence Henry

Art Unit

Examiner Name

Attorney Docket Number

C 2766 PCT/US

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Date _____

Considered

1006 Reg'd PCT/PTO, 16 JUN 2005

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/539879
		Filing Date	
		First Named Inventor	Florence Henry
		Art Unit	
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number	C 2766 PCT/US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Charrouf et al., "Ethnoeconomical, Ethnomedical, and Phytochemical Study of Argania Spinosa (L.) Skeels: A Review", Jour. of Ethnopharmacology, vol. 67, 1992, pgs 7-14, XP002242296	
		Z. Charrouf, "Triterpenes et Sterols Extraits de la Pulpe D'Argania Spinosa (L.) Sapotaceae", Plantes Medicinales et Phytotherapie, vol.25, 1991, pgs 112-117; XP000619575	
		R. Maurin, "L'Huile D'Argan Argania Spinosa (L.) Skeels Sapotaceae, Mise au Point", O.C.L. Oleagineux Corps Gras Lipides, vol. 39, 1992, pgs 139-146; XP002037529	
		Alaoui et al., "Activite Analgesique et Anti-Inflammatoire des Saponines D'Argania Spinosa Analgesic and Antiinflammatory Activity of Argania Spinosa Saponins", Annales Pharmaceutiques Francaises, vol.56, 1998, pgs 220-228; XP000995497	
		Charrouf et al., "Triterpenoid Saponins from Argania Spinosa", Phytochemistry, vol.31, 1992, pgs 2079-2086; XP001157414	
		Tahrouch et al., "Polyphenol Investigation of Argania Spinosa (Sapotaceae) Endemic Tree from Morocco", Acta Botanica Gallica, vol.147, 2000, pgs 225-232; XP000996078	
		Hiipakka et al., "Structure-activity Relationships for Inhibition of Human 5-alpha-reductases by polyphenols", Biochemical Pharmacology, vol.63, 2002, pgs 1165-1176; XP002242332	
		Alaoui et al., "Activite analgesique et anti-inflammatoire des saponines d'Argania spinosa", Annales pharmaceutique francaises, 1998, pgs 220-228	
		Oulad-Ali et al., "Structure Elucidation of Three Triterpene Glycosides from the Trunk of Argania spinosa", J.Nat.Prod., 1996, pgs 193-195	
		Hagers Handbuch der pharmazeutischen Praxis, vol. 2, 1991, pgs 1026-1030	
		Bernard et al., "Expression of type 1 5-alpha-reductase and metabolism of testosterone in reconstructed human epidermis (SkinEthic®): a new model for screening skin-targeted androgen modulators", Int.J.Cosmetic Science, pgs 397-407	
		Berrada et al., "Mise en évidence expérimentale des effets antihypertenseurs et hypocholestérolémiants de l'huile d'Argan, Argania sideroxylon", Therapie 2000, pgs 375-378 (listed on European Search Report which is unavailable).	

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

if you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

DSO/mc G/IDC/C2766idc